As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

10x Genomics, a medical technology company with impressive revenue growth, ... 10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses. Jan. 20, 2024 2:20 AM ET 10x Genomics, Inc. ...

10x Genomics: Wouldn't Touch This, Even With A 10x10 ... it would have to double revenues every year for the next six years before hitting $15 ... heavy insider selling, mediocre growth rates, ...

Even when you lose money, you don't have to lose ... In the last three years, 10x Genomics saw its revenue grow by 13% per year, compound. That's a fairly respectable growth rate.

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was ...

10x Genomics reported solid year-over-year improvement with its Q4 results. However, the company's 2022 revenue guidance was weaker than expected. The headwinds that 10x faces could be temporary.

While 10x Genomics seems to be in a decent position, ... (at the same burn rate). 10x Genomics' cash burn of US$113m is about 2.3% of its US$5.0b market capitalisation.

[10x Genomics]. 10x Genomics today filed an amended up-to-$362.25 million proposed initial public offering (IPO) that would be possibly triple, but no less than double ... on a rate of $8.4 ...

10x Genomics (TXG) could be a ... all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more ...

Given this risk, we thought we'd take a look at whether 10x Genomics (NASDAQ:TXG) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at ...

For Immediate ReleaseChicago, IL – October 29, 2024 – Today, Zacks Equity Research like Inspire Medical Systems INSP, 10x Genomics TXG and Omnicell, Inc. OMCL.